Isotopic labeling of organic compounds is crucial for advancements in life sciences and is extensively utilized in drug discovery. While isotopic labeling is widely applied to small molecules, research on isotopically labeled biologics such as peptides, antibodies, or enzymes remains less developed, despite the increasing prevalence of these larger biologics in the pharmaceutical industry as transformative treatments for patients. We report the development of an in situ prepared catalyst for Hydrogen Isotope Exchange reactions with deuterium or tritium gas as the isotope source to selectively label peptides in aqueous solutions. The method requires only low amounts of catalyst and provides the radiolabeled peptide in a single reaction step with sufficient specific activity for biological in-vitro experiments, paving the way for future developments and applications in biological based drugs studies. Furthermore, we have identified a substrate-mediated formation of the active catalytic species, leading to the high selectivity in this late-stage functionalization approach of complex peptide compounds. DFT calculations and NMR studies have identified the intermediate species involved. The reported insights accelerate the access to radiolabeled tracers to understand biological processes, as well as offer future opportunities for highly selective C-H activation and C-C or C-X bond formation to achieve highly selective late-stage functionalization products.
Martinelli et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: